Long‐term 4‐year safety of saxagliptin in drug‐naive and metformin‐treated patients with Type 2 diabetes. Issue 12 (19th July 2013)

• Record Type: Journal Article
• Authors: Rosenstock, J.; Gross, J. L.; Aguilar‐Salinas, C.; Hissa, M.; Berglind, N.; Ravichandran, S.; Fleming, D.
• Is Part Of: Diabetic medicine. Volume 30:Issue 12(2013:Dec.)
• Page Start: 1472
• Page End: 1476
• Publication Date: 2013-07-19
• Subjects: Diabetes -- Periodicals; 616.462
• DOI: 10.1111/dme.12267
• Languages: English
• ISSNs: 0742-3071

Abstract

<abstract abstract-type="main" id="dme12267-abs-0001"> <title>Abstract</title> <sec id="dme12267-sec-0001" sec-type="section"> <title>Aims</title> <p>To evaluate the safety of saxagliptin ± metformin over 4 years in patients with Type 2 diabetes mellitus.</p> </sec> <sec id="dme12267-sec-0002" sec-type="section"> <title>Methods</title> <p>Drug‐naive (<italic>n</italic> = 401; study 11) or metformin‐treated (<italic>n</italic> = 743; study 14) adults with HbA<sub>1c</sub> of 53–86 mmol/mol (7.0–10%) were enrolled in two randomized, placebo‐controlled, double‐blind trials of saxagliptin 2.5, 5 or 10 mg/day. Patients rescued during or completing 24 weeks of treatment could continue in a 42‐month long‐term blinded phase, for which the primary goal was assessment of safety and tolerability. Between‐group efficacy was not evaluated in the long‐term phase of study 11. Time to rescue or discontinuation because of inadequate glycaemic control, change from baseline in HbA<sub>1c</sub> and percentages of patients achieving HbA<sub>1c</sub> < 53 mmol/mol (< 7.0%) were assessed in study 14.</p> </sec> <sec id="dme12267-sec-0003" sec-type="section"> <title>Results</title> <p>No new safety findings were noted during the long‐term phase. Most adverse events were mild or moderate, with slightly greater frequency of upper respiratory infections with saxagliptin. Hypoglycaemic event rates were similar with saxagliptin and placebo. In study 14, time to rescue or discontinuation because of inadequate glycaemic control was longer with saxagliptin plus metformin than for placebo plus metformin. From baseline to week 154, HbA<sub>1c</sub> decreased with saxagliptin but increased with placebo.</p> </sec> <sec id="dme12267-sec-0004" sec-type="section"> <title>Conclusion</title> <p>Saxagliptin monotherapy or add‐on to metformin is generally safe and well tolerated, with no increased risk of hypoglycaemia, for up to 4 years.</p> </sec> </abstract>